

ACCELERON PHARMA INC  
 Form 4  
 December 10, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 George Jean

(Last) (First) (Middle)

C/O ADVANCED TECHNOLOGY VENTURE, 500 BOYLSTON STREET, SUITE 1380

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 ACCELERON PHARMA INC [XLRN]

3. Date of Earliest Transaction (Month/Day/Year)  
 12/08/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(A) or (D)	Price			
Common Stock	12/08/2014		S	83,143 (1)	\$ 45.33 (2)	1,819,920 (3)	I	See footnotes (4) (5)
Common Stock	12/08/2014		S	5,486 (6)	\$ 46.02 (7)	1,814,434 (8)	I	See footnotes (4) (5)
Common Stock	12/09/2014		S	8,778 (9)	\$ 40.11 (10)	1,310,650 (11)	I	See footnotes (4) (5)

## Edgar Filing: ACCELERON PHARMA INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director    10% Owner    Officer    Other

George Jean  
C/O ADVANCED TECHNOLOGY VENTURE  
500 BOYLSTON STREET, SUITE 1380  
BOSTON, MA 02116

X

## Signatures

/s/ Jean George                      12/10/2014

\_\_Signature of                      Date  
Reporting Person

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents 77,891 shares, 3,126 shares, 1,502 shares, 464 shares and 160 shares that were held directly, and sold, by Advanced Technology Ventures VII, L.P. ("ATV VII"), Advanced Technology Ventures VII (B), L.P. ("ATV VII B"), Advanced Technology Ventures VII (C), L.P. ("ATV VII C"), ATV Entrepreneurs VII, L.P. ("ATV VII E") and ATV Alliance 2003, L.P. ("ATV 2003"), respectively.

(2) Represents weighted average price. The shares were sold at prices ranging from \$45.00 to \$45.58. The reporting person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

(3)

## Edgar Filing: ACCELERON PHARMA INC - Form 4

Represents 1,704,950 shares, 68,416 shares, 32,886 shares, 10,157 shares and 3,511 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.

ATV Associates VII, L.L.C. ("ATV A VII") is the general partner of ATV VII, ATV VII B, ATV VII C and ATV VII E and exercises voting and dispositive authority over the shares held by ATV VII, ATV VII B, ATV VII C and ATV VII E. Jean George is a managing director of ATV A VII and exercises voting and dispositive decisions of ATV A VII collectively with each of four other managing directors. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.

- (4) 

ATV Alliance Associates, L.L.C. ("ATV Alliance LLC") is the general partner of ATV 2003 and exercises voting and dispositive authority over the shares held by ATV 2003. Voting and dispositive decisions of ATV Alliance LLC are made by Ms. George. Ms. George disclaims beneficial ownership of these securities and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of her pecuniary interest therein.
- (5) 

Represents 5,139 shares, 206 shares, 99 shares, 31 shares and 11 shares that were held directly, and sold, by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.
- (6) 

Represents weighted average price. The shares were sold at prices ranging from \$46.00 to \$46.25. The reporting person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- (8) 

Represents 1,699,811 shares, 68,210 shares, 32,787 shares, 10,126 shares and 3,500 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively.
- (9) 

Represents 4,994 shares, 2,812 shares and 972 shares that were held directly, and sold, by ATV A VII, ATV VII E and ATV 2003, respectively. The 4,994 shares sold by ATV A VII were previously reported as indirectly held through the reporting person's interests in ATV VII, ATV VII B and ATV VII C. Such shares were received by ATV A VII on December 8, 2014 by virtue of pro-rata in-kind distributions of common stock of the Issuer by ATV VII, ATV VII B and ATV VII C without consideration to their respective limited partners and ATV A VII, their general partner.
- (10) 

Represents weighted average price. The shares were sold at prices ranging from \$40.00 to \$40.51. The reporting person will provide upon request, to the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- (11) 

Represents 1,227,853 shares, 49,271 shares, 23,684 shares, 7,314 shares and 2,528 shares held directly by ATV VII, ATV VII B, ATV VII C, ATV VII E and ATV 2003, respectively. The shares held directly by ATV VII, ATV VII B and ATV VII C reflect the pro-rata in-kind distributions described in footnote (9) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.